摘要
INTRODUCTION Despite the known benefits of antipsychotic medications,they have been associated with increased risks of cardiometabolic side effects.Antipsychotic-induced adverse cardiometabolic effects,such as weight gain,high blood pressure,alterations in glucose metabolism and lipid dysregulation,are well-recognised risk factors for cardiovascular diseases(CVDs)and diabetes.1 Clinical guidelines call for regular physical health assessments and laboratory monitoring as a means to prevent and detect adverse cardiometabolic effects of antipsychotic medications.However,recent evidence suggests that cardiovascular condi-tions remain the key causes of death among people using antipsychotic medications,suggesting suboptimal screening and moni-toring practices.Suboptimal cardiometabolic screening among antipsychotic users can hinder the early detection of high-risk people and delay receiving proper management.
基金
This study was funded by the University of Birmingham.
